Your browser is no longer supported. Please, upgrade your browser.
Settings
VXRT [NASD]
Vaxart, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own0.60% Shs Outstand109.82M Perf Week-18.45%
Market Cap742.55M Forward P/E- EPS next Y-0.17 Insider Trans-41.42% Shs Float108.76M Perf Month18.26%
Income-46.90M PEG- EPS next Q-0.12 Inst Own34.30% Short Float23.54% Perf Quarter-31.23%
Sales1.70M P/S436.80 EPS this Y57.80% Inst Trans-0.10% Short Ratio1.44 Perf Half Y23.16%
Book/sh1.12 P/B5.84 EPS next Y58.50% ROA-23.40% Target Price- Perf Year156.47%
Cash/sh1.12 P/C5.85 EPS next 5Y- ROE-30.30% 52W Range2.23 - 24.90 Perf YTD14.54%
Dividend- P/FCF- EPS past 5Y45.00% ROI-24.60% 52W High-73.73% Beta0.32
Dividend %- Quick Ratio10.90 Sales past 5Y-15.30% Gross Margin- 52W Low193.27% ATR1.02
Employees28 Current Ratio10.90 Sales Q/Q-89.70% Oper. Margin- RSI (14)47.45 Volatility13.47% 14.42%
OptionableYes Debt/Eq0.00 EPS Q/Q5.40% Profit Margin- Rel Volume0.57 Prev Close7.20
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume17.77M Price6.54
Recom2.00 SMA20-3.23% SMA500.37% SMA200-9.25% Volume10,217,147 Change-9.17%
Aug-12-20Reiterated H.C. Wainwright Buy $7 → $17
Jul-13-20Initiated B. Riley FBR Buy $22
May-09-21 02:14PM  
May-07-21 08:00AM  
06:10AM  
May-06-21 11:37AM  
06:35AM  
06:00AM  
May-04-21 04:07PM  
09:57AM  
08:00AM  
07:01AM  
05:18AM  
May-03-21 05:06PM  
04:51PM  
11:35AM  
09:15AM  
08:00AM  
05:42AM  
Apr-30-21 06:17PM  
Apr-29-21 08:00AM  
Apr-27-21 06:05AM  
Apr-26-21 08:00AM  
Apr-23-21 08:00AM  
Apr-22-21 08:00AM  
06:35AM  
Apr-21-21 05:51AM  
Apr-14-21 06:12AM  
Apr-01-21 07:31AM  
06:09AM  
Mar-25-21 11:46AM  
Mar-21-21 08:00AM  
Mar-16-21 04:12PM  
Mar-13-21 06:00AM  
Mar-11-21 09:05PM  
Mar-10-21 06:33AM  
Mar-06-21 08:00AM  
06:50AM  
06:00AM  
Mar-05-21 10:11AM  
06:00AM  
Mar-04-21 04:01PM  
Mar-02-21 02:30PM  
04:23AM  
Mar-01-21 06:04AM  
Feb-25-21 04:01PM  
Feb-24-21 04:01PM  
07:47AM  
Feb-18-21 05:45PM  
Feb-15-21 06:30AM  
Feb-12-21 10:47AM  
Feb-10-21 08:08AM  
Feb-09-21 07:31AM  
Feb-06-21 06:45AM  
Feb-05-21 02:53PM  
07:03AM  
Feb-04-21 03:26PM  
10:09AM  
05:52AM  
03:13AM  
Feb-03-21 08:29PM  
08:25PM  
04:26PM  
11:28AM  
10:06AM  
08:57AM  
08:30AM  
05:31AM  
Feb-02-21 07:10AM  
Jan-30-21 06:15AM  
Jan-29-21 08:00PM  
Jan-28-21 01:36PM  
09:00AM  
Jan-27-21 04:04PM  
08:30AM  
Jan-26-21 08:30AM  
Jan-25-21 05:35PM  
Jan-22-21 06:09AM  
04:31AM  
Jan-19-21 08:56AM  
Jan-13-21 07:34AM  
07:02AM  
Jan-09-21 06:13AM  
Jan-08-21 06:15PM  
09:55AM  
06:05AM  
Jan-07-21 07:00AM  
Jan-06-21 09:17AM  
Jan-03-21 06:11AM  
Jan-02-21 06:36AM  
Jan-01-21 06:10AM  
Dec-29-20 05:51AM  
Dec-23-20 06:55AM  
Dec-22-20 06:48AM  
Dec-21-20 09:00AM  
Dec-18-20 07:22AM  
Dec-17-20 07:03AM  
Dec-16-20 06:14AM  
Dec-13-20 02:02PM  
Dec-11-20 10:38PM  
08:59AM  
Dec-10-20 12:04PM  
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tucker SeanChief Scientific OfficerMar 16Option Exercise6.491,0066,52948,053Mar 19 05:04 PM
Latour WouterDirectorMar 04Option Exercise0.77150,000115,500150,000Mar 05 04:03 PM
Latour WouterDirectorMar 04Sale6.04150,000906,4500Mar 05 04:03 PM
Latour WouterDirectorNov 23Sale6.32333,3342,108,1380Nov 23 08:18 PM
Tucker SeanChief Scientific OfficerAug 13Option Exercise6.494,02626,12951,679Aug 14 04:21 PM
ARMISTICE CAPITAL, LLCDirectorJun 29Sale8.299,385,38677,804,850145,523Jun 30 05:54 PM
ARMISTICE CAPITAL, LLCDirectorJun 26Sale10.3818,226,667189,192,8035,440,000Jun 30 05:54 PM
ARMISTICE CAPITAL, LLCDirectorJun 03Sale2.77400,0001,108,0007,000,000Jun 03 05:45 PM
ARMISTICE CAPITAL, LLCDirectorJun 02Sale2.75800,0002,200,0007,400,000Jun 03 05:45 PM
ARMISTICE CAPITAL, LLCDirectorJun 01Sale2.74200,000548,0008,200,000Jun 03 05:45 PM
ARMISTICE CAPITAL, LLCDirectorMay 27Sale2.61200,000522,0008,400,000May 29 05:22 PM
ARMISTICE CAPITAL, LLCDirectorMay 22Sale2.86200,000572,0008,600,000May 22 05:29 PM
ARMISTICE CAPITAL, LLCDirectorMay 21Sale2.97400,0001,188,0008,800,000May 22 05:29 PM
ARMISTICE CAPITAL, LLCDirectorMay 20Sale3.191,150,0003,668,5009,200,000May 22 05:29 PM
ARMISTICE CAPITAL, LLCDirectorMay 18Sale2.86650,0001,859,00010,350,000May 18 05:25 PM
ARMISTICE CAPITAL, LLCDirectorMay 15Sale2.82458,6391,293,36211,000,000May 18 05:25 PM
ARMISTICE CAPITAL, LLCDirectorMay 14Sale3.02834,6692,520,70011,458,639May 18 05:25 PM
ARMISTICE CAPITAL, LLCDirectorMay 13Sale2.97525,6161,561,08012,293,308May 13 05:37 PM
ARMISTICE CAPITAL, LLCDirectorMay 12Sale3.021,581,0764,774,85012,818,924May 13 05:37 PM
ARMISTICE CAPITAL, LLCDirectorMay 11Sale2.791,300,0003,627,00014,400,000May 13 05:37 PM